Obstetrics & Gynecology Doctors in New Canaan, CT Accepting Medicare

4 Obstetrics & Gynecology doctors found. Showing 1 - 4

Dr. Mindy Carol Fishman, M.D. Obstetrics & Gynecology - Gynecology Medicare: Medicare Enrolled Practice Location: 46 Charter Oak Dr, New Canaan, CT 06840 Phone: 203-594-9171    Fax: 203-594-9171

Christina Chang, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 39 Pine St, New Canaan, CT 06840 Phone: 203-801-4318    Fax: 203-801-4324

Sara L. S. Coca, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 161 Cherry St, New Canaan, CT 06840 Phone: 203-276-4282    Fax: 203-276-4283

Stephen M Gallousis, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 161 Cherry St, New Canaan, CT 06840 Phone: 203-276-4282    Fax: 203-276-4283

News Archive

Feeling anxious about your waistline?

A new study has found that middle-aged women face a high risk of developing anxiety, one of the most prevalent mental health disorders, due to their BMI.

Nanotags pinpoint multiple cancer markers in live animals

Using nanoparticles designed specifically to produce a bright Raman spectroscopic signal, a team of investigators at the Center for Cancer Nanotechnology Excellence Focused on Therapy Response (Stanford University Center for Cancer Nanotechnology Excellence [CCNE]) has shown that it can simultaneously track as many as 10 different optical tags in a living animal.

UIC researchers develop transgenic Alzheimer's mouse with apoE4 gene

Researchers at the University of Illinois at Chicago College of Medicine have developed a transgenic mouse that carries a human gene known to increase risk of Alzheimer's 15-fold. This new mouse mimics the genetics of the human disease more closely than any of the dozen existing mouse models and may prove more useful in the development of candidate drugs to prevent or treat the disease.

Janssen submits canagliflozin NDA with FDA for treatment of type 2 diabetes

Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.

Read more Medical News

› Verified 7 days ago